 |
市場調查報告書
商品編碼
2084833
纖維瘤市場：按藥物類型、通路和地區分類Desmoid Tumors Market, By Drug Type, By Distribution channel, By Geography |
||||||
價格
簡介目錄
據估計，到 2026 年，纖維瘤市值為 33.061 億美元，預計到 2033 年將達到 54.139 億美元。預計從 2026 年到 2033 年，其複合年成長率將達到 7.3%。
| 分析範圍 | 分析詳情 | ||
|---|---|---|---|
| 基準年 | 2025 | 市場規模（2026 年） | 33.061億美元 |
| 效能數據 | 2020-2024 | 預測期 | 2026-2033 |
| 預測期（2026-2033 年）複合年成長率 | 7.30% | 預計金額（2033 年） | 54.139億美元 |
纖維瘤是一種起源於結締組織的異常增生，結締組織賦予骨骼、韌帶和肌肉等結構強度和柔軟性。纖維瘤呈纖維狀，與疤痕組織非常相似。由於纖維瘤不會轉移到其他部位，因此通常不被認為是癌性（惡性）腫瘤。然而，纖維瘤會侵襲周圍組織，手術切除難度很高。即使看似完全切除，這些腫瘤也常常復發。纖維瘤最常見的症狀是疼痛。其他徵兆和症狀通常是由腫瘤侵襲周圍組織引起的，並且因腫瘤的大小和位置而異。
市場動態
該市場的主要企業專注於研發治療纖維瘤的藥物，預計將推動預測期內的市場成長。例如，2022年7月，專注於發現和商業化用於治療罕見腫瘤和高侵襲性癌症的小分子藥物的臨床階段腫瘤公司Ayala Pharmaceuticals, Inc.宣布，其正在進行的RINGSIDE II/III期臨床試驗（關鍵性試驗）A部分取得了積極的中期結果，該試驗旨在評估AL102在纖維瘤中的療效。 AL102是一種口服藥物，是一種強效且特異性的γ-分泌酶抑制劑（GSI）。此外，資助纖維瘤研究的「纖維瘤基金會」的存在預計也將推動該國預測期內的市場成長。例如，加拿大纖維瘤基金會（DFC）是一家註冊的加拿大慈善機構，致力於資助纖維瘤治療的研究。 DFC致力於資助纖維瘤研究，並探索治療這種罕見疾病的方法。 DFC支持不同機構的研究人員合作，以加速治療方法的研發。
本報告的主要特點
- 本報告揭示了各個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
- 此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要公司採取的競爭策略的重要見解。
- 本節根據公司概況、產品系列、主要趨勢、財務表現和策略等各種參數，對全球纖維瘤市場的主要參與者進行介紹。
- 本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、技術更新、市場擴張和行銷策略做出明智的決策。
- 《全球纖維瘤市場》報告面向該行業的眾多相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
- 相關人員可以透過分析全球纖維瘤市場中使用的各種策略矩陣來促進決策。
目錄
第1章：分析目標與假設
- 分析目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章：市場動態、監管與趨勢分析
- 市場動態
- 促進因素
- 抑制因子
- 機會
- 影響分析
- 監管趨勢
- 市場趨勢
- 主要進展
- 流行病學
- PEST分析
- 救贖方案
- 管道分析
- 協作場景
- 治療方案分析
- 對治療的安全性和有效性進行分析
- 作用部位（作用機轉）
- 纖維瘤治療流程
- 疾病意識計劃
- 風險和不良反應
- 各國醫療保健成本
- 未滿足的需求
- 治療率
第4章：全球纖維瘤市場：依藥物類型分類（2021-2033 年）
- 非類固醇消炎劑（NSAIDs）
- 標靶治療
- 化療
- 荷爾蒙療法
- 其他
第5章：全球纖維瘤市場：依通路分類（2021-2033 年）
- 醫院藥房
- 零售藥房
- 網路藥房
第6章 全球纖維瘤市場：依地區分類（2021-2033 年）
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
- 歐洲
- 英國
- 德國
- 法國
- 義大利
- 西班牙
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太國家
- 中東
- GCC
- 以色列
- 其他中東國家
- 非洲
- 北非
- 中非
- 南非
第7章 競爭情勢
- 熱圖分析
- 市佔率分析
- Horizon Therapeutics Plc
- Strides Pharma Science Limited
- Teva Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals LLC
- Hikma Pharmaceuticals PLC
- Natco Pharma Ltd
- Lupin
- Zydus Lifesciences
- Mylan NV
- Assertio Holdings, Inc.
- Mayne Pharma Group Limited
- Alembic Pharmaceuticals Limited
- Aprazer
- Ayala Pharmaceuticals
- SpringWorks Therapeutics, Inc.
- Iterion Therapeutics
- Novartis AG
- Apotex Inc.
- Bayer AG
- Sun Pharmaceutical Industries Ltd.
- Reddy's Laboratories Ltd.
- Endo International plc
- Abbott
- Getwell Pharmaceuticals
第8章
- 分析方法
- 關於 Coherent Market Insights
簡介目錄
Product Code: CMI5449
Desmoid Tumors Market is estimated to be valued at USD 3,306.1 Mn in 2026 and is expected to reach USD 5,413.9 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7.3% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 3,306.1 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.30% | 2033 Value Projection: | USD 5,413.9 Mn |
A desmoid tumor is an abnormal growth that arises from connective tissue, which is the tissue that provides strength and flexibility to structures such as bones, ligaments, and muscles. Desmoid tumors are fibrous, much like scar tissue. They are generally not considered cancerous (malignant) because they do not spread to other parts of the body. However, they can aggressively invade the surrounding tissue and can be very difficult to remove surgically. These tumors often recur, even after apparently complete removal. The most common symptom of desmoid tumors is pain. Other signs and symptoms, which are often caused by growth of the tumor into surrounding tissue, vary based on the size and location of the tumor.
Market Dynamics
Key players operating in the market are focused on developing drugs for the treatment of desmoid tumors which is expected to drive the market growth over the forecast period. For instance, in July 2022, Ayala Pharmaceuticals, Inc., a clinical-stage oncology company focusing on discovering and commercializing small molecule medicines for patients with uncommon tumors and aggressive cancers, announced positive interim findings from Part A of the ongoing RINGSIDE Pivotal Phase 2/3 clinical study assessing AL102 in desmoid tumors. AL102 is an oral gamma-secretase inhibitor that is powerful and specific GSI. Moreover, the presence of desmoid tumor foundation providing funds for desmoid tumor research, is expected to drive the market growth in the country over the forecast period. For instance, Desmoid Tumour Foundation of Canada (DFC) is a registered Canadian charity dedicated to funding research for cure for desmoid tumors. DFC is dedicated to funding desmoid tumor research and finding a cure for this rare disease. DFC supports the collaboration between researchers from different institutions to expedite the development of cure.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global desmoid tumor market based on the following parameters - Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies.
- Key companies covered as a part of this study Horizon Therapeutics Plc, Strides Pharma Science Limited, Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Hikma Pharmaceuticals PLC, Natco Pharma Ltd, Lupin, Zydus Lifesciences, Mylan N.V., Assertio Holdings, Inc., Mayne Pharma Group Limited, Alembic Pharmaceuticals Limited, Aprazer, Ayala Pharmaceuticals, SpringWorks Therapeutics, Inc., Iterion Therapeutics, Novartis AG, Apotex Inc., Bayer AG., Sun Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories Ltd., Endo International plc, Abbott, and Getwell Pharmaceuticals
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global desmoid tumor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global Desmoid Tumors Market.
Market Segmentation
- By Drug Type (Revenue, USD Mn, 2021 - 2033)
- Non-steroidal anti-inflammatory drugs (NSAIDs)
- Targeted Therapy
- Chemotherapy
- Hormone Therapy
- Others
- By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- North Africa
- Central Africa
- South Africa
- Key Players
- Horizon Therapeutics Plc
- Strides Pharma Science Limited
- Teva Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals LLC
- Hikma Pharmaceuticals PLC
- Natco Pharma Ltd
- Lupin
- Zydus Lifesciences
- Mylan N.V.
- Assertio Holdings, Inc.
- Mayne Pharma Group Limited
- Alembic Pharmaceuticals Limited
- Aprazer
- Ayala Pharmaceuticals
- SpringWorks Therapeutics, Inc.
- Iterion Therapeutics
- Novartis AG
- Apotex Inc.
- Bayer AG.
- Sun Pharmaceutical Industries Ltd
- Reddy's Laboratories Ltd.
- Endo International plc
- Abbott
- Getwell Pharmaceuticals
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Impact Analysis
- Regulatory Scenario
- Market Trends
- Key Developments
- Epidemiology
- PEST Analysis
- Reimbursement Scenario
- Pipeline Analysis
- Collaboration Scenario
- Treatment Option Analysis
- Treatment Safety and Efficacy Analysis
- Site of Activity (Mode of Action)
- Treatment Algorithm for Desmoid Tumours
- Disease Awareness Programs
- Risk and Adverse effects
- Healthcare spending by Country
- Unmet Needs
- Treatment Rate
4. Global Desmoid Tumors Market, By Drug Type, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Non-steroidal anti-inflammatory drugs (NSAIDs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Targeted Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Hormone Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
5. Global Desmoid Tumors Market, By Distribution Channel, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
6. Global Desmoid Tumors Market, By Region, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (USD Mn)
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (USD Mn)
- North Africa
- Central Africa
- South Africa
7. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Horizon Therapeutics Plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Strides Pharma Science Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Amneal Pharmaceuticals LLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Hikma Pharmaceuticals PLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Natco Pharma Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Lupin
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Zydus Lifesciences
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Assertio Holdings, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Mayne Pharma Group Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Alembic Pharmaceuticals Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Aprazer
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Ayala Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- SpringWorks Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Iterion Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Apotex Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Reddy's Laboratories Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Endo International plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Abbott
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Getwell Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Horizon Therapeutics Plc
8. Section
- Research Methodology
- About us
